Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

Some copy number alterations (CNAs) have independent prognostic significance for adults with acute lymphoblastic leukemia (ALL).

[1]  M. Tormo,et al.  Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols , 2014, Cancer.

[2]  J. Downing,et al.  Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[4]  J. Esteve,et al.  Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Downing,et al.  A Revised Definition for Cure of Childhood Acute Lymphoblastic Leukemia , 2014, Leukemia.

[6]  W. Evans,et al.  Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. , 2013, Blood.

[7]  M. Valsecchi,et al.  What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? , 2013, Haematologica.

[8]  C. Harrison,et al.  Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features , 2013, Haematologica.

[9]  J. Soulier,et al.  Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia , 2013, Haematologica.

[10]  M. Schrappe,et al.  Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia , 2012, Leukemia.

[11]  M. Tallman,et al.  IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Foà,et al.  CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients , 2011, Clinical Cancer Research.

[13]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[14]  Kevin K Dobbin,et al.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.

[15]  C. Harrison,et al.  Evaluation of multiplex ligation‐dependent probe amplification as a method for the detection of copy number abnormalities in B‐cell precursor acute lymphoblastic leukemia , 2010, Genes, chromosomes & cancer.

[16]  M. Greaves,et al.  Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. , 2010, Blood.

[17]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[18]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[19]  R. Foà,et al.  IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[21]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[22]  S. Knuutila,et al.  CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. , 2008, Leukemia research.

[23]  M. Tormo,et al.  Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Nutt,et al.  The transcriptional regulation of B cell lineage commitment. , 2007, Immunity.

[25]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[26]  M. Knowles,et al.  Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.

[27]  M. D. Boer,et al.  CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia , 2005, Leukemia.

[28]  J. Hernández-Rivas,et al.  Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. , 2005, Haematologica.

[29]  P. Burton,et al.  Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. , 2001, Blood.

[30]  T. Taki,et al.  Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. , 2000, Leukemia research.

[31]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[32]  K. Georgopoulos,et al.  Zinc finger‐mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. , 1996, The EMBO journal.